A Phase 2 interventional study of Durvalumab in Non-small Cell Lung Cancer, sponsored by AstraZeneca. Completed at 35 sites in 6 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-01-10.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.
Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 35th largest by enrollment, is one of 14 that started in 2020, is one of 58 in phase 2, and was the 55th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
AstraZeneca · Sites in Australia, Georgia, Poland and 2 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
ETOP IBCSG Partners Foundation · Sites in Australia, Austria, Belgium and 7 more countries
Ages 18+
Idris Bahce · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, durvalumab is the treatment under test here. Read study by study →
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 62 · Phase 3 17 · Phase 4 2
First in 2013; this study’s year is marked. 14 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 94 interventional studies. Of the 47 that completed or were terminated, 27 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 94 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 25 open now, 78 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 81st largest by enrollment of the 137 interventional ones that give a count, is one of 11 that started in 2020, is one of 38 in phase 2, and was the 128th registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
8 of the studies testing durvalumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04465968Phase 3National Cancer Center Hospital EastEfficacy and Safety of CRT, Durvalumab and Surgery for SST | 2027-08-31 |
| NCT03965468ETOP IBCSG Partners FoundationImmunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC | 2026-12 |
| NCT04245514Swiss Cancer InstituteMultimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | 2026-12-07 |
| NCT06908070Idris BahceChemoradiotherapy With Surgery Followed by Consolidation Durvalumab | 2026-12-17 |
| NCT05206812Yonsei UniversityWindow of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among AstraZeneca’s 209 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a Phase II open-label, single-arm, multicenter, international study to evaluate the clinical activity of durvalumab in patients with Stage III unresectable NSCLC who are deemed to be ineligible for chemotherapy per Investigator assessment. Patients will be enrolled into 2 cohorts according to radiotherapy pretreatment dose (Cohort A: standard radiation therapy [60 gray (Gy) ± 10% or hypofractionated bioequivalent dose (BED)]; Cohort B: palliative radiation therapy [40 to \< 54 Gy or hypofractionated BED])
This is a Phase II open-label, single-arm, multicenter, international study to evaluate the clinical activity of durvalumab in patients with Stage III unresectable NSCLC who have an Eastern Cooperative Oncology Group (ECOG) PS of 0 to 2 and who were treated with radiotherapy but are ineligible for chemotherapy. Patients will be enrolled into 2 cohorts according to the dose of radiotherapy received prior to study entry (Cohort A: Standard Radiotherapy [60 Gy ± 10% or hypofractionated BED]; Cohort B: Palliative Radiotherapy [40 to \< 54 Gy or hypofractionated BED]). Patients must not have progressed following radiation therapy, and radiation therapy must be completed within 6 weeks (42 days) prior to first study drug administration. The last dose of radiation therapy is defined as the day of the last radiation treatment session. All patients will receive 1500 mg durvalumab via IV infusion every 4 weeks (q4w) for up to a maximum of 12 months (up to 13 doses/cycles)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have adequate organ and marrow function as defined below:
Exclusion Criteria:
Exclusion criteria for participation in the optional genetics research component of the study include: a) Previous bone marrow transplant b)Nonleukocyte-depleted whole blood transfusion within 120 days of genetic sample collection.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received standard radiotherapy \[60 gray (Gy) ± 10% or hypofractionated BED\] prior to study entry.
Drug: Durvalumab
Patients received palliative radiotherapy \[40 to \< 54 Gy or hypofractionated BED\] prior to study entry.
Drug: Durvalumab
All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.
Also known as: MEDI4736
Number of Patients With Grade 3 and Grade 4 Possibly-related Adverse Events (PRAEs)
The safety and tolerability profile of durvalumab as defined by Grade 3 and Grade 4 PRAEs within 6 months from the initiation of durvalumab treatment. A PRAE was any TEAE with a possible relatedness to durvalumab, or where the relatedness was missing. If relatedness of a TEAE was missing at the primary DCO (30 March 2023) the TEAE was considered a PRAE.
Time frame: From first dose of durvalumab treatment until 6 months after initiation of durvalumab treatment
Median Progression-free Survival (mPFS)
Progression-free survival is defined as the time from the date of first dose of durvalumab until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient discontinues durvalumab or receives another anticancer therapy prior to progression according to RECIST 1.1 as assessed by the Investigator. Patients who had not progressed or died at the time of analysis were censored at the date of their last evaluable tumor assessment. If a patient progressed or died after two or more missed visits, they were censored at the date of the latest evaluable assessment prior to the missed visits.
Time frame: From the first date of treatment until the date of objective disease progression or death or data cut-off date (36 months)
Progression-free Survival at 6 Months (PFS6)
Progression-free survival is defined as the time from the date of first dose of durvalumab until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient discontinues durvalumab or receives another anticancer therapy prior to progression according to RECIST 1.1 as assessed by the Investigator. Patients who had not progressed or died at the time of analysis were censored at the date of their last evaluable tumor assessment. If a patient progressed or died after two or more missed visits, they were censored at the date of the latest evaluable assessment prior to the missed visits.
Time frame: From the first date of treatment until the date of objective disease progression or death (6 months)
Progression-free Survival at 12 Months (PFS12)
Progression-free survival is defined as the time from the date of first dose of durvalumab until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient discontinues durvalumab or receives another anticancer therapy prior to progression according to RECIST 1.1 as assessed by the Investigator. Patients who had not progressed or died at the time of analysis were censored at the date of their last evaluable tumor assessment. If a patient progressed or died after two or more missed visits, they were censored at the date of the latest evaluable assessment prior to the missed visits.
Time frame: From the first date of treatment until the date of objective disease progression or death (12 months)
Median Overall Survival (mOS)
The OS is defined as the time from the date of first dose of durvalumab until death due to any cause. Patients who were not known to have died at the time of analysis were censored at the last recorded date when they were known to have been alive.
Time frame: From the first date of treatment until death or data cut-off due to any cause (36 months)
Overall Survival at 12 Months (OS12)
The OS is defined as the time from the date of first dose of durvalumab until death due to any cause. Patients who were not known to have died at the time of analysis were censored at the last recorded date when they were known to have been alive.
Time frame: From the first date of treatment until death due to any cause (12 months)
Objective Response Rate (ORR)
The ORR is the proportion (%) of patients with an overall response of complete response (CR) or partial response (PR) (confirmed by a follow-up scan at least 4 weeks after showing CR or PR) per RECIST 1.1 criteria. CR is disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \< 10 mm. PR is at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
Time frame: From 8 weeks ±1 week after durvalumab treatment initiation and continue every 8 weeks (q8w) ±1 week through 48 weeks and every 12 weeks (q12w) ±1 week until disease progression or data cut-off (36 months)
Duration of Response (DoR)
The DoR is defined as the time from the date of first documented response (which is subsequently confirmed) until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.
Time frame: From 8 weeks ±1 week after durvalumab treatment initiation and continue every 8 weeks (q8w) ±1 week through 48 weeks and every 12 weeks (q12w) ±1 week until disease progression or data cut-off (36 months)
Lung Cancer Mortality
The lung cancer mortality (NSCLC-related death) is assessed using the deaths which are reported as 'NSCLC-related' and is defined as the time (days) from the date of first dose of durvalumab until date of death due to lung cancer.
Time frame: From date of treatment start until death due to lung cancer (36 months)
Number of Patients With Events (AEs)
The safety and tolerability profile of durvalumab treatment, including all adverse events (AEs) was assessed.
Time frame: From screening (Day -28) till data cut-off (36 months)
Number of Patients With Adverse Events of Special Interests (AESIs)
The safety and tolerability profile of durvalumab treatment, including all adverse events (AEs) was assessed. An AESI is an AE of scientific and medical interest specific to the understanding of durvalumab. AESIs for durvalumab include, but are not limited to, events with a potential inflammatory or immune-mediated mechanism and which may require more frequent monitoring and/or interventions such as steroids, immunosuppressants and/or hormone replacement therapy. Here, number of patients experienced AESIs are presented. Serious adverse event of special interests (SAESIs).
Time frame: From screening (Day -28) till data cut-off (36 months)
Number of Patients With Immune-mediated Adverse Events (imAEs)
The safety and tolerability profile of durvalumab treatment, including all adverse events (AEs) was assessed. An imAE is defined as an AESI that is associated with drug exposure and is consistent with an immune-mediated mechanism of action and where there is no clear alternate etiology. Here, number of patients experienced imAEs are presented. Immune-mediated serious adverse events (imSAEs)
Time frame: From screening (Day -28) till data cut-off (36 months)
Patients were enrolled and received study treatment at 29 sites in 5 countries (France, Italy, Poland, Russian Federation, and Spain). The data in this report are based on study start date (first patient enrolled: 26 November 2020 till final analyses data cut-off date of 06 December 2023.
| Milestone | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) |
|---|---|---|
| Started | 53 | 49 |
| Completed | 53 | 49 |
| Not completed | 0 | 0 |
The safety and tolerability profile of durvalumab as defined by Grade 3 and Grade 4 PRAEs within 6 months from the initiation of durvalumab treatment. A PRAE was any TEAE with a possible relatedness to durvalumab, or where the relatedness was missing. If relatedness of a TEAE was missing at the primary DCO (30 March 2023) the TEAE was considered a PRAE.
| Participants | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Durvalumab Total |
|---|---|---|---|
| Number of Patients With Grade 3 and Grade 4 Possibly-related Adverse Events (PRAEs) | 5 | 5 | 10 |
Progression-free survival is defined as the time from the date of first dose of durvalumab until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient discontinues durvalumab or receives another anticancer therapy prior to progression according to RECIST 1.1 as assessed by the Investigator. Patients who had not progressed or died at the time of analysis were censored at the date of their last evaluable tumor assessment. If a patient progressed or died after two or more missed visits, they were censored at the date of the latest evaluable assessment prior to the missed visits.
| Months | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Durvalumab Total |
|---|---|---|---|
| Median Progression-free Survival (mPFS) | 10.3 (7.49 to 16.56) | 7.6 (5.55 to 11.04) | 9.2 (7.39 to 11.93) |
Progression-free survival is defined as the time from the date of first dose of durvalumab until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient discontinues durvalumab or receives another anticancer therapy prior to progression according to RECIST 1.1 as assessed by the Investigator. Patients who had not progressed or died at the time of analysis were censored at the date of their last evaluable tumor assessment. If a patient progressed or died after two or more missed visits, they were censored at the date of the latest evaluable assessment prior to the missed visits.
| Percentage of patients | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Durvalumab Total |
|---|---|---|---|
| Progression-free Survival at 6 Months (PFS6) | 67.1 (51.96 to 78.43) | 59.3 (43.38 to 72.07) | 63.3 (52.62 to 72.25) |
Progression-free survival is defined as the time from the date of first dose of durvalumab until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient discontinues durvalumab or receives another anticancer therapy prior to progression according to RECIST 1.1 as assessed by the Investigator. Patients who had not progressed or died at the time of analysis were censored at the date of their last evaluable tumor assessment. If a patient progressed or died after two or more missed visits, they were censored at the date of the latest evaluable assessment prior to the missed visits.
| Percentage of patients | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Durvalumab Total |
|---|---|---|---|
| Progression-free Survival at 12 Months (PFS12) | 46.8 (31.88 to 60.36) | 31.8 (18.13 to 46.32) | 39.6 (29.28 to 49.76) |
The OS is defined as the time from the date of first dose of durvalumab until death due to any cause. Patients who were not known to have died at the time of analysis were censored at the last recorded date when they were known to have been alive.
| Months | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Durvalumab Total |
|---|---|---|---|
| Median Overall Survival (mOS) | 21.1 (11.60 to NA) | 16.8 (10.64 to NA) | 21.1 (14.75 to NA) |
The OS is defined as the time from the date of first dose of durvalumab until death due to any cause. Patients who were not known to have died at the time of analysis were censored at the last recorded date when they were known to have been alive.
| Percentage of patients | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Durvalumab Total |
|---|---|---|---|
| Overall Survival at 12 Months (OS12) | 64.0 (49.01 to 75.58) | 65.5 (49.87 to 77.26) | 64.7 (54.21 to 73.34) |
The ORR is the proportion (%) of patients with an overall response of complete response (CR) or partial response (PR) (confirmed by a follow-up scan at least 4 weeks after showing CR or PR) per RECIST 1.1 criteria. CR is disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \< 10 mm. PR is at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
| Percentage of patients | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Durvalumab Total |
|---|---|---|---|
| Objective Response Rate (ORR) | 34.0 (21.5 to 48.3) | 24.5 (13.3 to 38.9) | 29.4 (20.8 to 39.3) |
The DoR is defined as the time from the date of first documented response (which is subsequently confirmed) until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.
| Weeks | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Durvalumab Total |
|---|---|---|---|
| Duration of Response (DoR) | 56.9 (31.00 to NA) | 34.1 (24.29 to NA) | 56.9 (31.14 to NA) |
The lung cancer mortality (NSCLC-related death) is assessed using the deaths which are reported as 'NSCLC-related' and is defined as the time (days) from the date of first dose of durvalumab until date of death due to lung cancer.
| Months | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Durvalumab Total |
|---|---|---|---|
| Lung Cancer Mortality | 30.9 (16.92 to NA) | NA (14.75 to NA) | 30.9 (16.82 to NA) |
The safety and tolerability profile of durvalumab treatment, including all adverse events (AEs) was assessed.
| Participants | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Durvalumab Total |
|---|---|---|---|
| Any AE | 50 | 49 | 99 |
| Any PRAE (Investigator-assessed [IA]) | 31 | 31 | 62 |
| Any AE of CTCAE Grade 3 or Grade 4 | 20 | 21 | 41 |
| Any AE of CTCAE Grade 3 or Grade 4, possibly related to durvalumab treatment (IA) | 6 | 5 | 11 |
| Any AE with outcome of death | 5 | 2 | 7 |
| Any AE with outcome of death, possibly related to treatment (IA) | 1 | 0 | 1 |
| Any SAE (including events with outcome of death) | 23 | 18 | 41 |
| Any SAE (including events with outcome of death), possibly related to treatment (IA) | 5 | 3 | 8 |
| Any AE leading to discontinuation of treatment | 13 | 9 | 22 |
| Any AE leading to discontinuation of treatment, possibly related to treatment (IA) | 7 | 5 | 12 |
| Any AE leading to treatment interruption | 25 | 23 | 48 |
| Any AE leading to treatment interruption, possibly related to treatment | 6 | 7 | 13 |
| Any AESI (including events with outcome of death) (IA) | 25 | 21 | 46 |
| Any AESI (including events with outcome of death), possibly related to treatment (IA) | 19 | 14 | 33 |
| Any Adverse event of potential interest (AEPI) (including events with outcome of death) (IA) | 21 | 22 | 43 |
| Any AEPI (including events with outcome of death), possibly related to treatment (IA) | 14 | 15 | 29 |
| Any imAE (IA) | 27 | 24 | 51 |
| Any imAE, possibly related to treatment (IA) | 26 | 24 | 50 |
The safety and tolerability profile of durvalumab treatment, including all adverse events (AEs) was assessed. An AESI is an AE of scientific and medical interest specific to the understanding of durvalumab. AESIs for durvalumab include, but are not limited to, events with a potential inflammatory or immune-mediated mechanism and which may require more frequent monitoring and/or interventions such as steroids, immunosuppressants and/or hormone replacement therapy. Here, number of patients experienced AESIs are presented. Serious adverse event of special interests (SAESIs).
| Participants | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Durvalumab Total |
|---|---|---|---|
| Any AESIs | 25 | 21 | 46 |
| Any AESIs of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 | 4 | 1 | 5 |
| Any SAESIs [including events with outcome = death]) | 4 | 1 | 5 |
| Any AESIs with outcome = death | 1 | 0 | 1 |
| Any AESIs, causally related to treatment | 19 | 14 | 33 |
| Any AESIs of CTCAE Grade 3 or 4, causally related to treatment | 4 | 1 | 5 |
| Any SAESIs, causally related to treatment | 4 | 1 | 5 |
| Any AESIs with outcome = death, causally related to treatment | 1 | 0 | 1 |
| AESIs: Received systemic corticosteroids | 5 | 8 | 13 |
| AESIs: Received high dose steroids | 4 | 6 | 10 |
| AESIs: Received endocrine therapy | 6 | 5 | 11 |
| AESIs: Received other immunosuppressants | 0 | 0 | 0 |
| Any AESIs leading to discontinuation of durvalumab treatment | 4 | 3 | 7 |
| AESIs: Event outcome resolved | 13 | 12 | 25 |
| AESIs: Event outcome not resolved | 11 | 9 | 20 |
The safety and tolerability profile of durvalumab treatment, including all adverse events (AEs) was assessed. An imAE is defined as an AESI that is associated with drug exposure and is consistent with an immune-mediated mechanism of action and where there is no clear alternate etiology. Here, number of patients experienced imAEs are presented. Immune-mediated serious adverse events (imSAEs)
| Participants | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Durvalumab Total |
|---|---|---|---|
| Any imAEs | 11 | 15 | 26 |
| Any imAEs of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 | 2 | 3 | 5 |
| Any imSAEs [including events with outcome = death]) | 3 | 2 | 5 |
| Any imAEs with outcome = death | 1 | 0 | 1 |
| Any imAEs, causally related to treatment | 10 | 12 | 22 |
| Any imAEs of CTCAE Grade 3 or 4, causally related to treatment | 2 | 3 | 5 |
| Any imSAEs, causally related to treatment | 3 | 2 | 5 |
| Any imAEs with outcome = death, causally related to treatment | 1 | 0 | 1 |
| imAEs: Received systemic corticosteroids | 7 | 13 | 20 |
| imAEs: Received high dose steroids | 5 | 7 | 12 |
| imAEs: Received endocrine therapy | 6 | 5 | 11 |
| imAEs: Received other immunosuppressants | 0 | 0 | 0 |
| Any imAEs leading to discontinuation of durvalumab treatment | 3 | 4 | 7 |
| imAEs: Event outcome resolved | 5 | 8 | 13 |
| imAEs: Event outcome not resolved | 5 | 7 | 12 |
Collected over From screening (Day -28) till data cut-off (36 months). Non-serious events are listed at a 2.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Durvalumab Cohort A: Standard Radiotherapy (RT) | 23/53 (43.4%) | 23/53 (43.4%) | 47/53 (88.7%) |
| Durvaumab Cohort B: Palliative Radiotherapy (RT) | 23/49 (46.9%) | 18/49 (36.7%) | 45/49 (91.8%) |
| Durvalumab Total | 46/102 (45.1%) | 41/102 (40.2%) | 92/102 (90.2%) |
| Event | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Durvalumab Total |
|---|---|---|---|
| Cardiac failureCardiac disorders | 1/53 | 4/49 | 5/102 |
| PneumoniaInfections and infestations | 3/53 | 2/49 | 5/102 |
| Atrial fibrillationCardiac disorders | 2/53 | 0/49 | 2/102 |
| Enterobacter sepsisInfections and infestations | 0/53 | 1/49 | 1/102 |
| Pneumonia bacterialInfections and infestations | 0/53 | 1/49 | 1/102 |
| Ischaemic strokeNervous system disorders | 0/53 | 1/49 | 1/102 |
| SyncopeNervous system disorders | 0/53 | 1/49 | 1/102 |
| Hypovolaemic shockVascular disorders | 0/53 | 1/49 | 1/102 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/53 | 1/49 | 1/102 |
| AspirationRespiratory, thoracic and mediastinal disorders | 0/53 | 1/49 | 1/102 |
| Event | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Durvalumab Total |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 13/53 | 6/49 | 19/102 |
| AstheniaGeneral disorders | 13/53 | 8/49 | 21/102 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/53 | 12/49 | 21/102 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 11/53 | 8/49 | 19/102 |
| ConstipationGastrointestinal disorders | 3/53 | 10/49 | 13/102 |
| FatigueGeneral disorders | 1/53 | 10/49 | 11/102 |
| HypothyroidismEndocrine disorders | 9/53 | 6/49 | 15/102 |
| PruritusSkin and subcutaneous tissue disorders | 5/53 | 8/49 | 13/102 |
| PyrexiaGeneral disorders | 8/53 | 8/49 | 16/102 |
| Decreased appetiteMetabolism and nutrition disorders | 8/53 | 6/49 | 14/102 |
The safety analysis set consisted of all patients who received at least one dose of durvalumab treatment.
| Age, Continuous(Years) | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Total |
|---|---|---|---|
| Mean | 74.7 ± 9.18 | 78.8 ± 6.71 | 76.7 ± 8.32 |
| Sex: Female, Male(Participants) | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Total |
|---|---|---|---|
| Female | 15 | 14 | 29 |
| Male | 38 | 35 | 73 |
| Race/Ethnicity, Customized(Participants) | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Total |
|---|---|---|---|
| White | 46 | 45 | 91 |
| Other | 1 | 0 | 1 |
| Unknown | 3 | 1 | 4 |
| Missing | 3 | 3 | 6 |
| Race/Ethnicity, Customized(Participants) | Durvalumab Cohort A: Standard Radiotherapy (RT) | Durvaumab Cohort B: Palliative Radiotherapy (RT) | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 5 |
| Not Hispanic or Latino | 45 | 43 | 88 |
| Missing | 6 | 3 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2020 to primary completion in Mar 2023, 28 months.
Results were first posted in Sep 2024, 1 year 5 months after primary completion. A results delay was requested in Feb 2024.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 28 months is below that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Durvalumab
Carcinoma, Non-Small-Cell Lung →